PF-Atlas › Clinical Trials › NCT03385668

Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies

Pirfenidone · Phase 2

Registry ID
NCT03385668
Phase
Phase 2
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
2018-01-31
Enrollment
7
Locations
1

About this trial

The purpose of this study is to determine wether pirfenidone is safe and effective in the treatment of pulmonary fibrosis with anti-myeloperoxydase (MPO) antibodies or pulmonary fibrosis with anti-MPO associated vasculitis.

View NCT03385668 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT03385668 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.